Want to join the conversation?
$CMS 2Q15 Call: CMS has been able to deliver consistent earnings growth of more than 7% each year for over a decade. With investment growth, operating cash flow as a percent of market cap has gone from less than peers five years ago to greater than peers now; additional growth will provide an even larger cash flow.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.